Background: Tau burden has been found to be involved in brain atrophy during aging, especially in regions such as the parahippocampal gyrus. However, how tau levels at baseline are associated with trajectories of tau accumulation, cortical thinning and cognitive impairment remains poorly understood. The goal of this study was to assess tau rate of change in patients between baseline Tau+ and Tau- patients. We also aimed to determine if tau status at baseline or rate of accumulation of tau interacted with the rate of cortical thinning of the parahippocampal regions, leading to an increased rate of change in cognition.
Method: We assessed 133 participants from the TRIAD cohort (mean age = 68.5 ± 8.9, 85 females) with at least two visits with tau-PET using [F]MK6240 and cortical thickness extracted using FreeSurfer 7. Average time between visits was 25.6 months. Patients were classified according to clinical status, Amyloid-β status and tau status at baseline (CU AB-Tau-, CU AB+Tau-, CU AB+Tau+, MCI AB+Tau-, MCI AB+Tau+, AD AB+Tau+). The tau-PET rate of change was calculated for each participant, voxelwise and with temporal meta-ROI. The MMSE rate of change was calculated to quantify cognitive decline over follow-up period. We assessed the voxelwise relationship between baseline tau status and tau-PET rate of change.
Results: We found a voxelwise positive association between rate of accumulation of tau and tau status at baseline in both anterior temporal lobes. Furthermore, we found an interaction effect between tau-PET at baseline and parahippocampal rate of atrophy on MMSE rate of change (standardized β = 0.48, p < 0.0001).
Conclusion: Our results suggest that tau status at baseline might impact the rate of accumulation of tau, and that higher baseline levels of tau interact with cortical thinning of parahippocampal regions, leading to faster rates of cognitive decline. Our results emphasize the importance of preventing tau burden to prevent faster pace of cognitive decline during the disease's trajectory.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/alz.085973 | DOI Listing |
Orphanet J Rare Dis
January 2025
Department of Cardiac Physiology, National Cerebral and Cardiovascular Center Research Institute, 6-1 Kishibe-Shimmachi, Suita, Osaka, 564-8565, Japan.
Background: Transient receptor potential cation channel subfamily V member 2 (TRPV2) functions as a stretch-sensitive calcium channel, with overexpression in the sarcolemma of skeletal and cardiac myocytes leading to detrimental calcium influx and triggering muscle degeneration. In our previous pilot study, we showed that tranilast, a TRPV2 inhibitor, reduced brain natriuretic peptide levels in two patients with muscular dystrophy and advanced heart failure. Building on this, we performed a single-arm, open-label, multicenter study herein to evaluate the safety and efficacy of tranilast in the treatment of advanced heart failure in patients with muscular dystrophy.
View Article and Find Full Text PDFBMC Geriatr
January 2025
Department of Neurology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Objectives: Freezing of Gait (FOG) is one of the disabling symptoms in patients with Parkinson's Disease (PD). While it is difficult to early detect because of the sporadic occurrence of initial freezing events. Whether the characteristic of gait impairments in PD patients with FOG during the 'interictal' period is different from that in non-FOG patients is still unclear.
View Article and Find Full Text PDFBMC Infect Dis
January 2025
Department of Disease Prevention and Control, Second Affiliated Hospital of Navy Medical University, Shanghai, China.
Background: Limited information is available regarding the changes in blood culture utilization following the COVID-19 pandemic. Blood culture utilization rate is a critical indicator of diagnostic efficiency for infectious diseases. This study aims to describe the impact of the COVID-19 pandemic on blood culture utilization rate in Shanghai.
View Article and Find Full Text PDFBMC Anesthesiol
January 2025
Department of Anesthesiology and Perioperative Medicine, The First Affiliated Hospital of Nanjing Medical University, No.300 of Guangzhou Road, Gulou District, Nanjing, Jiangsu, 210029, China.
Objective: The objective of this study is to investigate bacterial proliferation within the internal circuits of anesthesia machines in post-anesthesia care units (PACUs) following the implementation of the new protocol, where 'a single dedicated external circuit is used for each individual patient.' This measure was introduced during the COVID-19 pandemic, in alignment with a novel prevention and control strategy.
Methods: Using the observational technique, we analyzed anesthesia machines in PACUs between July and September 2022.
Lung
January 2025
National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, UMR 754, ERN-LUNG, Lyon, France.
Purpose: In the INBUILD trial in patients with progressive pulmonary fibrosis (PPF), nintedanib slowed the decline in forced vital capacity (FVC) versus placebo, with a safety profile characterised mainly by gastrointestinal events. INBUILD-ON, the open-label extension of INBUILD, assessed the safety of nintedanib during longer-term treatment. Data on FVC were collected.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!